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Left atrial appendage occlusion: 
What is its role today?
Occlusion of the LAA is an option in patients with non-valvular AF 
in whom OACT is recommended (CHA2DS2-VASc score >1) but 
either absolutely contra-indicated, perceived to be too risky by the 
treating physician due to relative contra-indications or refused. 
Below is a brief review of the current literature regarding the 
LAA occluders currently available in South Africa – the Watchman 
(Boston Scientific) and the Amplatzer Cardiac Plug (St Jude).
LEFT ATRIAL APPENDAGE OCCLUDERS
The Watchman device
This is the only device for which there is currently a randomised 
controlled trial of the device versus warfarin – the Protect-AF 
trial.(8,10) Following on from this trial eligible patients were enrolled 
into a non-randomised registry, the Continued Access Protocol,(9) 
mainly to allow for further study of periprocedural complications, 
those being pericardial effussion, device embolisation, stroke and 
air embolism. A second randomised study, the Prevail Study,(11) 
although not yet published (publication imminent) is presented 
below. Therefore to participate in these trials (as described below) 
eligible patients had to be able to take warfarin.
PROTECT-AF trial 
The Protect-AF trial(8) was a non-inferiority trial that randomised 
707 patients with non-valvular AF and a CHADS2 score of at least 
1 to either the Watchman device (n=463) or continued warfarin 
(n=244) in a 2:1 ratio. After device implantation warfarin was 
continued for 45 days, followed by clopidogrel for 4.5 months and 
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The left atrial appendage (LAA), an embryonic remnant, is the 
source of approximately 90% of emboli originating from the heart 
in patients with atrial fibrillation (AF).(1) Use of oral anti-coagulant 
therapy (OACT), such as warfarin, has been shown to reduce 
the incidence of stroke and other embolic events by approxi-
mately 66% in patients where the INR is well controlled (target INR 
2-3).(2) However, achieving this INR target is difficult and many 
patients are either under or over anti-coagulated, putting them at 
risk of embolic events and/or major bleeding complications. The 
newer OACs such as Rivaroxoban and Dabigatran, depending 
on dosage used, have been shown to be equivalent or mildly 
superior to warfarin in terms of efficacy and safety.(3,4)
However, all OACTs are contra-indicated in a large number of 
patients due to a history of previous intra-cerebral bleeding, gastro-
intestinal bleeding of unknown cause, recurrent falls and frailty, a 
high risk of bleeding (HASBLED score >3), and drug interactions. 
Even in patients without contra-indications to OACT, use is often 
less than 50%.(5)
Surgical amputation of the LAA at the time of cardiac surgery has 
been shown to reduce the incidence of stroke in patients with 
AF.(6) On this basis percutaneous exclusion of the LAA has been 
developed – initially using the Plato device(7) (no longer in pro-
duction), and followed by the Watchman (Boston Scientific) and 
Amplatzer Cardiac Plug (ACP) (St Jude).
In many patients with paroxysmal or permanent non-
valvular atrial Fibrillation and a CHA2DS2-VASc score of 
2 or more, warfarin or other newer oral anti-coagulant 
therapies are contra-indicated, or are not prescribed, for 
a variety of reasons. These patients are therefore at risk 
of serious life threatening thrombo-embolic events parti-
cularly large stroke. Percutaneous occlusion of the left 
atrial appendage, the source of the majority of these emboli, 
is a therapy which should be considered in these patients. 
There is growing evidence that this procedure is as good as, 




















lifelong aspirin. This study showed the device was non-inferior to 
Warfarin in terms of stroke prophylaxis, with a trend towards 
superiority.
In the successfully treated population the primary efficacy event 
rate in the intervention group who discontinued warfarin was 1.9 
per 100 patient years compared to 4.6 per 100 patient years in the 
control group who received warfarin (RR 0.40). Warfarin was 
discontinued in 88% of the patients in the intervention group at 
45 days after trans-oesophageal echocardiogram (TOE) showed 
complete closure or minimal peri-device flow into the left atrial 
appendage. At 6 months 92% of patients had discontinued warfarin 
after repeat TOE. Primary safety events occurred at a higher rate in 
the intervention group than in the control group (7.4 per 100 
patient years vs 4.4 per 100 patient years. RR 1.69). The most 
frequent primary safety event in the intervention group was serious 
pericardial effusion which occurred in 4.8% of patients. No patients 
with pericardial effusion died. Most safety events occurred during 
the first 3 implant procedures (12.3% versus 5.9% subsequently).
In summary, the early results of this study showed occlusion of the 
LAA with the Watchman device was as effective as warfarin in 
preventing embolic events but at a cost of possible serious adverse 
events at the time of implantation.
The Continued Access Protocol (CAP) registry(9)
This is a non-randomised registry of patients undergoing Watchman 
implantation (Continued Access Protocol [CAP] Registry; n=460 
patients). The safety end point included bleeding- and procedure-
related events (pericardial effusion, stroke, device embolisation). 
The results showed a significant decline in the rate of procedure- or 
device-related safety events within 7 days of the procedure, which 
occurred in 7.7% of patients in Protect-AF and in 3.7% of patients 
in CAP Registry (p=0.007). Serious pericardial effusion within 7 
days of implantation, which had made up >50% of the safety events 
in PROTECT AF, was lower in the CAP Registry (5.0% versus 2.2%, 
respectively; P=0.019). Similarly the rate of procedure related 
stroke improved with experience (0.9% versus 0%, respectively; 
P=0.039). Overall the functional impact of these safety events, as 
defined by significant disability or death, was superior in the 
Watchman group compared to the warfarin group in PROTECT-
AF study. 
In summary, the CAP registry confirmed the findings seen in the 
Protect-AF study that serious adverse events at the time of 
implantation of the device decreased significantly with increasing 
operator experience. 
The PROTECT-AF -4 year follow up(10)
Longer term (4 year) follow up of the PROTECT-AF trial showed 
the device group achieved superiority for the composite endpoint 
of all stroke, cardiovascular or unexplained death and systemic 
embolism. The observed adverse event rate was 2.3% and 3.8% 
in the Watchman and Control groups, respectively (RR= 0.60, 
posterior probability of superiority = 96%), demonstrating a 40% 
relative risk reduction in the Watchman group. In addition all 
cause mortality in the Watchman group was superior to Control: 
3.2% for Watchman and 4.8% for Control, representing a 34% 
relative risk reduction in all-cause mortality in the Watchman group 
(HR = 0.66, p=0.0379). Cardiovascular mortality in the Watchman 
group was superior to Control: 1.0% for Watchman and 2.4% for 
Control, demonstrating a 60% relative risk reduction in cardio-
vascular death in the Watchman group (HR= 0.40, p=0.0045).
In conclusion, the PROTECT-AF 4 year follow-up data showed that 
the Watchman device was statistically superior to warfarin for 
reducing the relative risk of the composite primary endpoint of 
cardiovascular death, all stroke and systemic embolisation, as well 
as both all-cause mortality and cardiovascular mortality. The long-
term efficacy from PROTECT-AF, coupled with the safety results 
of PREVAIL(11) and CAP(9) studies, provide strong evidence that 
Watchman is a viable alternative to chronic warfarin therapy for 
stroke reduction in non-valvular AF patients.
The PREVAIL study(11)
This trial has not been published yet. The PREVAIL trial was 
designed to confirm the results of the PROTECT-AF trial and 
validate the safety of the implant procedure, as requested by 
the FDA due to concern of safety events during implantation 
seen in the Protect-AF study. A total of 407 patients were ran-
domised 2:1 device vs. warfarin control. Patients enrolled must 
have been warfarin eligible and have a CHADS2 score of ≥2. 
Procedural safety events occurred in only 2.2% of patients receiving 
the device. Pericardial effussion occurred in 1.9% of patients. 
Longer term efficacy outcome data is still awaited. 
FIGURE 1: Thrombus seen in left atrial appendage on trans-
esophageal echocardiogram.
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The ASAP study(12)
This non-randomised study prospectively enrolled 150 patients 
with non-valvular AF and a CHADS2 score of at least 1 who were 
INELIGIBLE for OACT. Patients underwent LAA closure with the 
Watchman device and were treated with clopidogrel for 6 months 
in addition to lifelong low dose aspirin. A history of bleeding (93%) 
was the most common reason for warfarin ineligibility.
After follow-up of 14.4 ± 8.6 months, the combined primary 
efficacy endpoint (ischaemic stroke, haemorrhagic stroke, systemic 
embolism, and cardiovascular/unexplained death) occurred in 8 
patients, a rate of 4.6 events per 100 patient-years. All-cause 
stroke or systemic embolism occurred in 4 patients (2.3% per year): 
ischaemic stroke in 3 patients (1.7% per year) and haemorrhagic 
stroke in 1 patient (0.6% per year). This ischaemic stroke rate 
was 77% less than that expected (7.3% per year) based on the 
CHADS2 scores of 2.8 ± 1.2 in this patient cohort.
Serious procedure- or device-related safety events occurred in 
8.7% of patients and included device embolisation without seque-
lae (n=2), pericardial effusion with (n=2) or without (n=3) tam-
ponade, and device thrombus with ischaemic stroke (n=1). Six 
cases of device-related thrombus were seen during follow-up, but 
only 1 was associated with stroke.
In summary, this non-randomised study showed it was safe to 
implant the Watchman device in patients who are unable to take 
OAC therapy, provided they are able to take dual anti-platelet 
therapy for 6 months post implantation.
THE AMPLATZER CARDIAC PLUG (ACP)
The ACP design is a modification of the Amplatzer septal occluder 
which has been used very effectively to percutaneously seal atrial 
septal defects and patent foramen ovale for a number of years. The 
use of dual anti-platelet therapy for 1-3 months post implantation 
has been shown to be adequate to prevent thrombo-embolism 
following device implantation in these patients.
There are no randomised trials comparing the ACP versus OACT
in patients with non-valvular AF, merely a series of registries(13-16) 
of how the ACP performed in patients who are unable to take 
warfarin. Compared to the predicted stroke rate according to the 
CHADS2 score, the actual stroke rate seen in these registries is 
approximately half of that predicted.
The randomised prospective Amplatzer Cardiac Plug Clinical Trial 
is currently enrolling up to 3 000 patients with non-valvular AF 
and a CHADS2 score >2 to ACP vs warfarin or dabigatran in 90 
centres across North America.(17)
The ACP is used extensively in Europe and Asia as an alternative 
to the Watchman device due to its perceived superiority in sealing 
the LAA orifice (Figure 2). 
Left atrial appendage closure with Amplatzer Cardiac Plug in 
atrial fi brillation: Initial European experience(13)
This early study is a retrospective data collection to evaluate pro-
cedural feasibility and safety up to 24 hours after implantation 
of the ACP in patients with non-valvular AF. Device implantation 
was successful in 132 of 137 attempted cases (96%). There were 
serious complications in 10 (7.0%) patients (3 patients with ischae-
mic stroke; 2 patients experienced device embolisation, both per-
cutaneously recaptured; and 5 patients with clinically significant 
pericardial effusions). Minor complications were insignificant peri-
cardial effusions in 4, transient myocardial ischaemia in 2, and loss 
of the implant in the venous system in one patient. It concluded 
that implantation of the ACP device is a feasible method for 
percutaneous occlusion of the LAA, with a safety event rate similar 
to that seen in the Watchman studies.
The European Prospective Observational Study(14)
This non-randomised observational study used the ACP in 
patients (N=204) with non-valvular AF who have contra-indica-
tions for OAC therapy. Following device implantation the 
patients took DAP for 1-3 months followed by low dose aspirin 
alone for at least 6 months. There was a 96.6% implantation 
success rate with a total safety event rate of 2.9% (serious peri-
cardial effusion 1.5%). There were no procedure related strokes 
or TIA. After 101 patient years follow up the actual stroke rate 
was 1.98%. The estimated annual stroke risk was 5.6% according 
to the average CHADS2 score of 2.6. Similar to the Watchman 
studies, procedural safety events were significantly reduced with 
increasing operator experience.
CONCLUSION
Percutaneous occlusion of the LAA in patients with non-valvular 
AF appears to be a safe and effective alternative to OAC therapy 
in patients who have contra-indications to this therapy. One may 
even speculate that the benefit of a device-based approach could 
be more pronounced in clinical practice than that observed in 
clinical trials, given the observation that even in patients after an 
ischaemic stroke, the persistent use of warfarin in clinical practice 
after 2 years was lower than 50%.(18) However, the compliance 
with anticoagulation may also improve with the novel anticoagu-
lants. Although currently there are only randomised trials using 
the Watchman device compared to warfarin, these trials prove 
the concept that percutaneous closure of the LAA is equivalent, 
if not superior in the long term, to warfarin. The use of the ACP 
is, I believe, a reasonable alternative to the Watchman device, as 
it safely and effectively seals off the LAA orifice. Both devices 



















FIGURE 2: Schematic diagrams illustrating the essential difference 
between ACP and Watchman devices.
Amplatzer Cardiac Plug
WATCHMAN device
ACP implantation is 
possible with shallow 





Potential source of leakage 
between device and LAA orifice
Deep LAA anatomy a prerequisite 
for WATCHMAN device
or the other may be better suited to that particular patient. 
Increasing operator experience with implantation has been 
shown in all studies to significantly reduce safety events. Therefore, 
I believe that it may be better for an operator to concentrate on 
using only one device initially, and become skilled at implanting 
that device, before implanting alternative devices as implantation 
techniques differ. Device implantation is difficult and requires a 
dedicated training programme and proctoring for at least the first 
3 - 10 cases. Implantation also requires the assistance of a skilled 
trans-oesophagealechocardiographer. In the future, if increasing 
long term data continue to show superiority of these devices 
versus OACT, these devices may even be considered as an alterna-
tive to OACT de novo in patients who do not want to take long 
term OACT
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